Annissa Kwok
Associate
Annissa Kwok is focused on intellectual property litigation, particularly proceedings under the Patented Medicines (Notice of Compliance) Regulations. Annissa Kwok completed the Canadian and American Juris Doctor Program at the University of Windsor Faculty of Law and the University of Detroit Mercy School of Law. Annissa previously attended the University of Toronto and completed an Honours Bachelor of Science in Human Biology, with a research focus in Arabidopsis thaliana gene expression.
Annissa has served as a litigator with Community Legal Aid in Windsor, Ontario, and as a member of the Federation of Asian Canadian Lawyers. After her first year of law school, Annissa interned for Beaumont Health in Dearborn, Michigan. In her second year of law school, Annissa was selected to represent University of Windsor in the International Criminal Court Moot Court Competition. Annissa and her team advanced to the semi-final round in White Plains, New York. Annissa worked at the International Property Law Clinic in Detroit, Michigan, and competed in the International Patent Drafting Competition hosted by the United States Patent and Trademark Office. She was invited to attend the 91st Annual Meeting of the Intellectual Property Institute of Canada in Niagara, Ontario. In her final year, Annissa was selected to represent University of Windsor in the 16th Annual Oxford International Intellectual Property Law Moot Competition held in Oxford, United Kingdom. Annissa was nominated and selected to be a member of the Michigan Intellectual Property Inn of Court.
Education
- H.B.Sc., University of Toronto
- J.D., University of Detroit Mercy
- J.D., University of Windsor
Bar Admission
- Ontario, 2019

My recent cases
Appeal of a trademark expungement case regarding Registration Nos. TMDA22577 and UCA44562 (HORLICKS)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,791,171 (apixaban)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,461,202 (apixaban)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,507,002 and 2,496,780 (silodosin)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,823,159, 2,634,310 and 2,547,113 (rivaroxaban)
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,823,159, 2,634,310 and 2,547,113 (rivaroxaban)
Trademark expungement regarding Registration Nos. TMDA22577 and UCA44562 (HORLICKS)
Patent infringement case regarding Patent No. 2,787,952 (bevacizumab) with counterclaim for infringement under the new Patented Medicines (Notice of Compliance) Regulations
More people

Warren Sprigings

Carol Hitchman

Dale Schlosser

Mary McMillan

Mingquan Zhang, Ph.D.

Meghan A. Dureen, Ph.D.

Nathaniel Dillonsmith

Kristina Zilic

Amisa Khan

Nick Kawar

Rae Daddon
